4D flow cardiovascular magnetic resonance derived energetics in the Fontan circulation correlate with exercise capacity and CMR-derived liver fibrosis/congestion

Friso M. Rijnberg1*, Jos J. M. Westenberg2, Hans C. van Assen2, Joe F. Juffermans2, Lucia J. M. Kroft2, Pieter J. van den Boogaard2, Covadonga Terol Espinosa de Los Monteros3, Evangeline G. Warmerdam5, Tim Leiner6, Heynric B. Grotenhuis5, Monique R. M. Jongbloed4, Mark G. Hazekamp1, Arno A. W. Roest3† and Hildo J. Lamb2†

Abstract

Aim: This study explores the relationship between in vivo 4D flow cardiovascular magnetic resonance (CMR) derived blood flow energetics in the total cavopulmonary connection (TCPC), exercise capacity and CMR-derived liver fibrosis/congestion.

Background: The Fontan circulation, in which both caval veins are directly connected with the pulmonary arteries (i.e. the TCPC) is the palliative approach for single ventricle patients. Blood flow efficiency in the TCPC has been associated with exercise capacity and liver fibrosis using computational fluid dynamic modelling. 4D flow CMR allows for assessment of in vivo blood flow energetics, including kinetic energy (KE) and viscous energy loss rate (EL).

Methods: Fontan patients were prospectively evaluated between 2018 and 2021 using a comprehensive cardiovascular and liver CMR protocol, including 4D flow imaging of the TCPC. Peak oxygen consumption ($VO_2$) was determined using cardiopulmonary exercise testing (CPET). Iron-corrected whole liver T1 (cT1) mapping was performed as a marker of liver fibrosis/congestion. KE and EL in the TCPC were computed from 4D flow CMR and normalized for inflow. Furthermore, blood flow energetics were compared between standardized segments of the TCPC.

Results: Sixty-two Fontan patients were included (53% male, 17.3 ± 5.1 years). Maximal effort CPET was obtained in 50 patients ($VO_2$ 27.1 ± 6.2 ml/kg/min, 56 ± 12% of predicted). Both KE and EL in the entire TCPC ($n=28$) were significantly correlated with cT1 ($r=0.50$, $p=0.006$ and $r=0.39$, $p=0.04$, respectively), peak $VO_2$ ($r=-0.61$, $p=0.003$ and $r=-0.54$, $p=0.009$, respectively) and % predicted peak $VO_2$ ($r=-0.44$, $p=0.04$ and $r=-0.46$, $p=0.03$, respectively). Segmental analysis indicated that the most adverse flow energetics were found in the Fontan tunnel and left pulmonary artery.

*Correspondence: f.m.rijnberg@lumc.nl
†Arno A. W. Roest and Hildo J. Lamb shared senior authorship
1 Department of Cardiothoracic Surgery, Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusions: Adverse 4D flow CMR derived KE and EL in the TCPC correlate with decreased exercise capacity and increased levels of liver fibrosis/congestion. 4D flow CMR is promising as a non-invasive screening tool for identification of patients with adverse TCPC flow efficiency.

Keywords: Fontan, 4D flow MRI, Viscous energy loss, FALD, Fibrosis, Exercise capacity

Introduction
The Fontan procedure provides a unique surgical solution for congenital heart disease patients with a functionally univentricular heart defect, by connecting the systemic venous return directly with the pulmonary arteries (i.e. the total cavopulmonary connection: TCPC). Consequently, the Fontan circulation requires increased central venous pressure (CVP) to overcome the serial resistance in the TCPC and pulmonary vascular bed to maintain an adequate cardiac output. The chronic exposure to elevated venous pressures provides a significant burden for upstream organs, including an almost universal occurrence of liver fibrosis [1]. Furthermore, the ability to increase preload and thereby cardiac output during exercise is limited leading to a diminished exercise capacity [2].

Being one of the few modifiable factors in the Fontan circulation, blood flow efficiency in the TCPC has been widely studied using predominantly in silico computational fluid dynamic (CFD) models [3–5]. Highly variable blood flow efficiency in the TCPC has been reported, related to the presence of energy-consuming geometric factors that can become apparent during follow-up [3, 5]. Recently, correlations were found between CFD-derived TCPC blood flow efficiency and clinical outcome, including liver fibrosis [6] and exercise capacity [7].

Drawbacks of CFD modelling are that it is time-consuming and requires expert knowledge and infrastructure, limiting widespread use in clinical care. 4D flow cardiovascular magnetic resonance imaging (CMR) is emerging as a non-invasive screening tool for visualization of energy-consuming flow patterns in the TCPC and quantification of flow-related hemodynamic parameters including kinetic energy (KE) and viscous energy loss rate (EL) [8–10]. The hypothesis in this study is that these in vivo 4D flow CMR-derived energetics in the TCPC are associated with exercise capacity and liver fibrosis/congestion. Subsequently, the aim of this study is to determine KE and EL in the TCPC using 4D flow CMR and to assess the relationship with exercise capacity and CMR-based assessment of liver fibrosis/congestion.

Materials and methods
Study population
Sixty-two Fontan patients were prospectively evaluated using a comprehensive cardiovascular and liver CMR research protocol, including 4D flow imaging of the TCPC, between 2018–2021 at the Leiden University Medical Center, Leiden, the Netherlands. The study was approved by the medical ethical review board of the Leiden University Medical Center (P18.024). Written informed consent was obtained from all patients and/or their parents. All patients > 8 years old without contraindications for CMR with a clinical indication for routine surveillance of the Fontan pathway using CMR were eligible for inclusion.

Cardiopulmonary exercise testing
Cardiopulmonary exercise testing (CPET) was performed on an upright bicycle ergometer (General Electric Healthcare, Chicago, Illinois, USA) including peak oxygen uptake (VO2) assessment. CPET was performed on the same day or within 6 months of CMR. A continuous incremental bicycle protocol was executed according to the Godfrey protocol [11]. Peak VO2 (ml/kg/min) and percentage of predicted peak VO2 (%) were determined in all patients that achieved maximal effort (respiratory exchange ratio > 1.0) using previously reported reference values [12].

Laboratory data
Standard laboratory assessment was performed on the same day or within 6 months of CMR, including liver enzymes, total protein, albumin, total bilirubin, and international normalized ratio (INR). Additionally, a feces sample was tested on alfa-1-antitrypsin excretion as a marker of (early) protein losing enteropathy. Results were interpreted using the hospital’s standard age- and gender-specific reference values.

Cardiovascular magnetic resonance
All CMR examinations were performed on a 3 T system (Ingenia, Philips Healthcare, Best, the Netherlands).

Multiparametric liver imaging
Patients underwent multiparametric liver imaging using proton density fat-fraction (PDFF), T2*, and iron-corrected T1 mapping (cT1) for the assessment of liver fat, iron, and fibrosis/inflammation/congestion, respectively (Liver MultiScan™, Perspectum Diagnostics Ltd., Oxford, UK) [13]. Patients underwent liver imaging after fasting for at least 4 h. No intravenous contrast agent was used.
Values were calculated from segmentation of whole liver regions (cT1 and PDFF) or one or more regions of interest (T2*) on one or more transversal slices. cT1 mapping allows for quantification of extracellular fluid in the liver, which is increased in both liver fibrosis, inflammation and venous congestion. Since inflammation is usually absent in liver fibrosis in Fontan patients [14] and liver enzymes are usually normal or only mildly elevated, elevated cT1 values in Fontan patients will predominantly reflect fibrosis and/or venous congestion. Reference values of PDFF, T2* and cT1 are <5.6%, >12.5 ms and 633–794 ms, respectively. [15–17] These metrics have been proven to be repeatable and reproducible across different manufacturers and field strengths [18]. All liver scans were anonymized and subsequently analyzed (Perspectum, Oxford, UK) using an online portal.

**Ventricular function**

Ventricular ejection fraction and cardiac output were calculated by ventricular volume analysis (MASS software, Leiden, the Netherlands) of multislice two-dimensional cine transversal images using a balanced steady-state-free-precession sequence. The cardiac index was derived by normalizing cardiac output for body surface area (Haycock).

**4D flow CMR**

Patients underwent retrospective electrocardiogram (ECG) and respiratory navigator-gated 4D flow CMR examination dedicated for imaging of the TCPC. Acquisition details for 4D flow CMR are covered in Additional file 1: Table S1. A velocity encoding of 80 cm/s resulted in minimal aliasing in only a few patients which could be corrected by build-in anti-aliasing software (CAAS, MR Solutions, PIE Medical Imaging BV, Maastricht, the Netherlands). No intravenous contrast was used for the 4D flow acquisition.

A 3D reconstruction of the TCPC was semi-automatically segmented on magnitude-weighted speed images of a time-averaged reconstruction of the 4D flow velocity field (CAAS v5.1, MR Solutions, Pie Medical Imaging). The region of interest covered the area between the Fontan tunnel (above entry of the hepatic veins), superior vena cava (SVC) (below the brachiocephalic vein) and the right- and left pulmonary arteries (PAs) up to the levels of the segmental branches. The right upper lobe branch was excluded from the segmentation since the resolution of the 4D flow CMR for this small vessel is insufficient [19].

Both the KE and EL of blood flow in the TCPC were computed from the 4D flow CMR velocity field using in-house developed software, as previously described [20]. KE represents the amount of energy in the blood flow due to its motion. EL represents the rate of kinetic energy lost in the blood flow due to friction and can be computed from three-dimensional velocity gradients derived from 4D flow CMR. EL was computed using the viscous dissipation function from the Navier–Stokes equation, assuming laminar blood flow [20]. The total amount of KE (in millijoule, [mJ]) and EL (in milliwatts, [mW]) within the TCPC is computed by summing voxel-wise energetics for each time-phase (24 phases per cardiac cycle). The cardiac-cycle averaged values are reported. Previous studies showed good to strong reproducibility of 4D flow based segmentation, flow quantification and quantification of hemodynamic energetics [21–24].

In patients in whom the entire TCPC was available for analysis, energetics were normalized for inflow (SVC + Fontan tunnel flow, in L/min); KE\_norm\_flow in mJ per L/min and EL\_norm\_flow in mW per L/min [25].

**Segmental analysis**

To further explore and compare the energetics in the specific components of the TCPC, a sub analysis was performed to determine segment-specific energetics (Fontan tunnel, central Fontan confluence, SVC, left PA (LPA) and right PA (RPA), using in-house developed software as previously described [25]. Additional benefit of this approach is that in patients with a fenestration closure device or PA stent in situ, in whom the entire TCPC cannot be segmented because of device-related flow artefacts, energetics in the TCPC segments without device-related artefacts can be studied. In these patients, only part of the Fontan tunnel (distal to the device) or PA (proximal to the stent) can be included in the segmentation. Segments with a length <1.5 cm were excluded from the analysis to ensure sufficient voxels for energetic analysis. [25].

In summary, the TCPC was automatically divided into 5 segments. Energetics within each segment were normalized for segment-specific inflow (Fontan confluence) or inflow + length (Fontan tunnel, SVC, LPA, RPA; KE\_norm\_flow+length and EL\_norm\_flow+length) [25]. The additional normalization for length in these segments is required as these segments are not always completely available for analysis (e.g. due to stent or device related artefacts) making direct comparison between complete and incomplete segments not possible.

Cross-sectional areas (CSA) normalized for body surface area (BSA) of the included conduit, SVC, LPA and RPA segments were determined perpendicularly to their centerlines at a 1 mm interval [21]. The mean CSA of each segment is reported.

[57x103] KE represents the amount of energy in the blood computed from the 4D flow CMR velocity field using the 4D flow CMR for this small vessel is insufficient [19].

[57x139] excluded from the segmentation since the resolution of the segmental branches. The right upper lobe branch was right- and left pulmonary arteries (PAs) up to the levels of vena cava (SVC) (below the brachiocephalic vein) and the Fontan tunnel (above entry of the hepatic veins), superior ing). The region of interest covered the area between the...
A flow chart of the study methods and performed analyses are reported in Additional file 1: Fig. S1.

Statistical analysis
Continuous data are presented as mean (standard deviation) or median (interquartile range, IQR), as appropriate. Normal distributions of continuous data were tested using the Shapiro–Wilk test. Pearson and/or Spearman correlation analysis (weak 0.3–0.5, moderate 0.5–0.7, strong ≥0.7–0.9 and excellent >0.9) was performed between the main endpoints (cT1 liver mapping and maximal exercise capacity) and CMR parameters; ventricular function and 4D flow energetics in the entire TCPC. Segment-specific energetics (Fontan tunnel, SVC, LPA and RPA) were compared with each other using the Kruskal Wallis test (adjusted by the Bonferroni method for multiple tests). Correlation analysis was performed between segment-specific energetics and normalized CSA. A p-value <0.05 was considered statistically significant. Data were analyzed with SPSS (version 25.0, Statistical Package for the Social Sciences, International Business Machines, Inc., Armonk, New York, USA) and GraphPad Prism (version 8.0, GraphPad Software, La Jolla, California, USA).

Results
Study population
Patient characteristics are shown in Table 1. Fifty-three percent of patients were male with a mean age at CMR of 17.3±5.1 years and mean time between Fontan completion and CMR of 13.6±4.8 years. The majority of patients (94%) underwent Fontan completion using a (fenestrated) 16–20 mm extracardiac Goretex conduit. Fenestrations closed spontaneously or were routinely closed after Fontan completion using a fenestration closure device. One patient still had a patent fenestration at time of CMR. All but two patients were in good clinical condition (New York Heart Association class I-II).

CPET and laboratory
CPET results are presented in Table 2. CPET was performed in 57 patients (92%), with 50 patients achieving maximal effort. Mean peak VO₂ was 27.1±6.2 ml/kg/min, 57%±12% of predicted peak VO₂.

Laboratory results are provided in Table 3. Total protein and albumin were normal in all but one patient with refractory protein losing enteropathy. Alanine aminotransferase, Aspartate aminotransferase and gamma glutamyltransferase levels were normal or only mildly elevated in the majority of patients.

Table 1 Patient characteristics

| Characteristic | Value |
|---------------|-------|
| Male/female   | 33/29 |
| Primary diagnosis, n (%) | |
| TA            | 14 (23) |
| HLHS          | 12 (19) |
| DILV + TGA    | 10 (16) |
| DORV          | 6 (10)  |
| uAVSD         | 5 (8)   |
| ccTGA         | 5 (8)   |
| PA + IVS      | 5 (8)   |
| Other         | 5 (8)   |
| Dominant ventricle | |
| Left, n (%)   | 35 (56) |
| Right, n (%)  | 21 (34) |
| Biventricular/indeterminate, n (%) | 6 (10) |
| Characteristics at Fontan procedure | |
| Previous bidirectional Glenn shunt, n (%) | 62 (100) |
| Age at Fontan, years | 3.7 (1.8) |
| Fontan technique LT/ECC | 4/58 |
| Implanted conduit size (16/18/20 mm), n | 30/22/6 |
| Fenestration, n (%) | 38 (61) |
| Characteristics at time of CMR | |
| Age at CMR, years | 17.3 (5.1) |
| Height, cm    | 167 (12) |
| BSA, m²       | 1.6 (0.3) |
| Time between Fontan and CMR, years | 13.6 (4.8) |
| NYHA-class I-II, n (%) | 60 (97) |
| Male/female, n | 33/29 |

Values are reported as mean (standard deviation) unless otherwise specified.
BSA, body surface area; TA, tricuspid atresia; HLHS, hypoplastic left heart syndrome; DILV, double inlet left ventricle; ccTGA, congenital corrected transposition of the great arteries; DORV, double outlet right ventricle; uAVSD, unbalanced atroventricular septal defect; PA + IVS, pulmonary atresia with intact ventricular septum; LT, lateral tunnel; ECC, extracardiac conduit, NYHA, New York Heart Association

Alfa-1-antitrypsin excretion in the feces was normal (n=48) or only mildly elevated (n=3) in all patients.

Comprehensive CMR analysis
Multiparametric liver imaging
Multiparametric liver imaging was performed in all patients. cT1 analysis could not be performed in one patient due to insufficient data quality. cT1 (reference 633–794 ms) was elevated in all patients (mean cT1 964±63 ms, range 824–1073 ms). T2* was within normal ranges (reference value >12.5 ms) in all patients (mean T2* 22.6±3.4 ms). Mean PDFF (reference value <5.6%) was 1.7±3.3%. Only one patient had an elevated PDFF of 27.1% indicating liver steatosis.
Table 2 CPET results

|                        | Mean (SD) | Range | Abnormal level, n (%) |
|------------------------|-----------|-------|-----------------------|
| SBP basal, mmHg        | 124 (15)  | 35–83 | 1 (2)                 |
| SBP peak, mmHg         | 172 (26)  | 18–54 | 2 (2)                 |
| RERpeak                | 1.1 (0.09)| 1.0–1.5| 3 (7)                 |
| Power, watt            | 131 (37)  | 1.0–1.5| 3 (7)                 |
| % predicted            | 68 (15)   | 1.0–1.5| 3 (7)                 |
| HRrest, bpm            | 82 (15)   | 1.0–1.5| 3 (7)                 |
| HRpeak, bpm            | 172 (17)  | 1.0–1.5| 3 (7)                 |
| % predicted            | 93 (10)   | 1.0–1.5| 3 (7)                 |
| HRRotate, bpm          | 91 (25)   | 1.0–1.5| 3 (7)                 |
| Maximal exercise (n = 50) |         |       |                       |
| Peak VO2, ml/kg/min    | 27.1 (6.2)|       |                       |
| % predicted            | 57 (12)   |       |                       |

Values are reported as mean (standard deviation). HRpeak, maximal heart rate at peak exercise; HRreserve, maximal heart rate-resting heart rate; HRrest, resting heart rate; RERpeak, respiratory exchange ratio at peak exercise; SBPbasal/peak, systolic blood pressure at rest/peak; VO2peak, oxygen uptake at peak exercise.

Table 3 Laboratory results

|                        | n | Mean (SD) | Range | Abnormal level, n (%) |
|------------------------|---|-----------|-------|-----------------------|
| Total protein, g/L     | 56| 71 (7)    | 35–83 | 1 (2)                 |
| Albumin, g/L           | 59| 48 (5)    | 18–54 | 1 (2)                 |
| Aspartate aminotransferase, U/L | 57| 32 (10) | 18–74 | 22 (39)               |
| Alanine aminotransferase, U/L | 58| 36 (16) | 15–111| 14 (24)               |
| Gamma glutamyltransferase, U/L | 56| 58 (40) | 18–185| 25 (45)               |
| Total bilirubin, µmol/L| 55| 15 (10)   | 5–49  | 13 (24)               |
| INR*, (reference ≤ 1.2)| 42| 1.1 (0.1)| 1.0–1.5| 3 (7)                 |
| Fecal alfa-1-antitrypsine, mg/g (reference < 0.4) | 51| 0.2 (0.1)| 0.1–0.7 | 3 (6) |
| NT-proBNP              | 57| 113 (99) | 23–446| 7 (12)                |

* Patients on oral anticoagulation were excluded. SD, standard deviation. INR, international normalized ratio; NT-proBNP, N-terminal pro brain natriuretic peptide

Segmental 4D flow CMR energetics

Results of segmental TCPC energetics are reported in Table 4. KE_{norm_flow}+length was lowest in the SVC and lower compared to the Fontan tunnel (p < 0.001), RPA (p = 0.002) and LPA (p < 0.001). KE_{norm_flow}+length was higher in the LPA compared to the RPA (p = 0.027). EL_{norm_flow}+length was higher in the conduit (p = 0.024) and LPA (p < 0.001) compared to the SVC and higher in the LPA compared to the RPA (p < 0.001). In the Fontan tunnel, mean CSA showed a strong negative correlation with KE_{norm_flow}+length (p = 0.80, p < 0.001) and EL_{norm_flow}+length (p = 0.78, p < 0.001, Additional file 1: Table S2). A weak correlation was found between mean LPA CSA and EL_{norm_flow}+length (p = 0.31, p = 0.034). Energetics in the RPA and SVC were not related to segment-specific CSA.

Ventricular function and 4D flow CMR energetics

Mean cardiac index and ejection fraction were 3.4 ± 0.1 L/min/m² and 48 ± 7%, respectively. 4D flow CMR of the TCPC was acquired in 61 patients. One patient wanted to stop with the CMR examination before acquisition of 4D flow CMR was completed. Five patients were excluded from 4D flow analysis due to insufficient image quality (excessive patient movement related, n = 4) or because of the presence of multiple central device-related artefacts affecting the majority of the TCPC. The total TCPC without device-related CMR artefacts was available for 4D flow energetic analysis in 28/56 patients (50%).

In the patients in whom the entire TCPC was available for analysis, KE_{norm_flow} and EL_{norm_flow} in the total TCPC were 0.26 ± 0.07 mW per L/min and 0.075 ± 0.022 mW per L/min inflow. Energetics were not significantly different between genders (p = 0.27–0.37). A significant positive correlation was observed for KE_{norm_flow} and EL_{norm_flow} with cT1 (r = 0.50, p = 0.006 and r = 0.39, p = 0.04, respectively, Fig. 1). An example of TCPC blood flow patterns, related energetics and cT1 liver mapping is shown for two extracardiac Fontan patients in Fig. 2. Furthermore, KE_{norm_flow} and EL_{norm_flow} showed a significant negative correlation with peak VO2 (r = −0.61, p = 0.003 and r = −0.54, p = 0.009, respectively) and % predicted peak VO2 (r = −0.44, p = 0.04 and r = −0.46, p = 0.03, respectively, Fig. 1). No significant correlations were found between cardiac index and KE_{norm_flow} and EL_{norm_flow} (r = −0.030, p = 0.83 and r = 0.048, p = 0.725, respectively) and between cardiac index and KE_{norm_flow} and EL_{norm_flow} (r = −0.189, p = 0.16 and r = −0.147, p = 0.28 respectively).

Discussion

This study for the first time shows the relationship between in vivo 4D flow CMR-derived TCPC blood flow energetics, exercise capacity and CMR-based assessment of liver fibrosis/congestion (cT1 mapping). Liver cT1 values were elevated in all patients at a mean age of 17 years, indicating universal liver fibrosis/congestion. KE_{norm_flow} and EL_{norm_flow} in the TCPC correlated with maximal exercise capacity and liver cT1, while conventional parameters as ventricular ejection fraction and cardiac index did not. The Fontan tunnel and LPA were the segments with most adverse energetics. EL_{norm_flow} was highest in patients with smallest Fontan tunnels raising concern on the current approach of Fontan completion with 16 to 20 mm rigid conduits.
Surgical construction of an energy efficient TCPC with low resistance is important to keep the increase in CVP and reduction of preload towards the single ventricle to a minimum [26]. An elevated CVP and reduced cardiac output play an important role in the occurrence of liver fibrosis and decreased exercise capacity, respectively. In silico CFD modelling studies have identified PA stenosis and undersized Fontan tunnels to be associated with reduced flow efficiency [4, 5, 27], which correlates with liver fibrosis stage and exercise capacity [6, 7]. Therefore, routine screening of Fontan patients on the occurrence of (subclinical) adverse TCPC flow efficiency is clinically relevant for timely identification of patients with adverse TCPC hemodynamics, in whom intervention may be beneficial.

Recently, 4D flow CMR has emerged as a promising non-invasive technique for quantification of in vivo TCPC flow efficiency. KE and EL in the TCPC are novel 4D flow CMR markers reflecting TCPC flow efficiency, influenced by adverse TCPC geometry (e.g. PA stenosis or undersized conduit) and related flow patterns. 4D flow CMR previously revealed adverse vortical/helical flow

---

**Fig. 1** Correlation analysis between kinetic energy (KE) (left) and viscous energy loss rate (EL) (right) in the total cavopulmonary connection (TCPC) with iron corrected T1 mapping (cT1); cT1 (upper panel), peak oxygen uptake (VO2) (middle panel) and % predicted peak VO2 (lower panel) are shown.
patterns in the Fontan confluence, PAs, or in a blind-ending pulmonary trunk, all areas associated with increased KE and EL [9, 25]. In this study, adverse 4D flow derived KE and EL in the TCPC correlated with reduced maximal exercise capacity and increased levels of liver fibrosis/congestion (cT1), and may therefore be important novel markers that can indicate adverse outcome.

**Exercise capacity**

Decreased exercise capacity in Fontan patients is predominantly caused by a limited capability to maintain preload and stroke volume of the single ventricle during exercise [2]. Importantly, resting cardiac index and ejection fraction did not correlate with exercise capacity, but adverse 4D flow energetics in the TCPC did show a significant correlation. This might be explained by the fact that increased EL in the TCPC may particularly affect preload and thus cardiac output during exercise conditions only, since energy loss in the TCPC increases non-linearly with exercise [28], and are therefore not captured by evaluation of resting cardiac function parameters.

**Liver fibrosis**

Presence of Fontan associated liver disease, including liver fibrosis, is universal in Fontan patients and the chronic exposure of the liver to an elevated CVP plays an important role [1]. The association between energetics and liver cT1 mapping can therefore be explained by the fact that elevated EL in the TCPC will require an increased CVP to maintain cardiac output. Fibrosis progression rate varies between patients and factors that lead to accelerated liver fibrosis are unknown as serial liver fibrosis assessment is lacking [29]. Future longitudinal studies with liver cT1 mapping could verify if patients with adverse TCPC energetics show faster progression in liver fibrosis.

**Liver cT1 mapping**

Gold standard liver biopsy is subject to sampling errors and its invasiveness prohibits routine serial assessment. In this study a novel non-invasive approach was used based on iron-corrected T1 mapping to quantify increased levels of extracellular liver fluid, which
is elevated in liver fibrosis and/or venous congestion. Although cT1 values showed good correlation with histologic liver fibrosis in adult patients with liver disease [15], validation in Fontan patients is currently lacking. Especially venous congestion will influence T1 values in Fontan patients since increased CVP has been correlated with increased levels of liver T1 [30]. Therefore, distinction between liver fibrosis or congestion due to increased CVP on elevated cT1 cannot be determined. However, since an increased CVP is associated with important morbidity such as PLE and liver fibrosis, measurement of cT1 as a combined marker of fibrosis/CVP is a promising non-invasive marker for adverse outcome.

**Segmental analysis**

Analysis of the TCPC segments that most severely affected the adverse energetics of the entire TCPC indicated that the Fontan tunnel and LPA are the areas to focus on for improved TCPC efficiency. Increased KE and EL in the conduit, carrying 70% of total systemic venous return, can be explained by the presence of undersized extracardiac conduits (IVC-conduit velocity mismatch) caused by somatic overgrowth [8], since a strong inverse correlation between conduit CSA and energetics was shown. LPA hypoplasia/stenosis, often observed in hypoplastic left heart syndrome patients, but also the presence of vortical flow in larger LPAs or in patients in whom the pulmonary trunk has not been detached, can explain the adverse energetics in the LPA. [9, 25].

**Limitations**

Compared to CFD, 4D flow CMR underestimates “true” energy loss and only captures relatively large-scale flow structures due to a limited spatial resolution. However, the relative performance of the TCPC between patients remains intact making comparison of TCPC energetics between Fontan patients still possible [31]. 4D flow CMR also does not capture the influence of respiration on TCPC blood flow [32], which could significantly affect energy losses [33]. Novel 5D flow CMR sequences can be of interest to study the effect of respiration on TCPC energetics [34]. TCPC energetics could only be linked to current cT1 values in this study. Since the occurrence of liver fibrosis is presumably time-related, correlation of TCPC energetics with longitudinal cT1 mapping will be of interest and is subject to future research. Liver cT1 mapping has been shown to predict mortality and liver-related events in patients with chronic liver disease [35], but its prognostic value in Fontan patients is currently unknown. Finally, energetics in the Fontan confluence segment could not be directly compared with the other four segments since Fontan confluence energetics were normalized for flow only and thereby not directly comparable with energetics in the other four segments.

**Conclusion**

Adverse 4D flow CMR derived kinetic energy and viscous energy loss rate in the TCPC significantly correlate with reduced exercise capacity and increased levels of liver fibrosis/congestion (cT1), while ventricular ejection fraction and cardiac index did not. Liver cT1 values were elevated in all patients indicating universal presence of liver fibrosis/congestion. The Fontan tunnel and LPA were the segments with most adverse energetics indicating potential room for improvement either at time of initial Fontan operation (e.g. implanting expandable conduits) or by intervention stenting/dilatation or possibly conduit replacement. 4D flow CMR is therefore promising as a non-invasive screening tool for identification of patients with adverse TCPC flow efficiency.
Abbreviations
BSA: Body surface area; CFD: Computational fluid dynamic; CMR: Cardiovascular magnetic resonance; CPET: Cardiopulmonary exercise testing; CSA: Cross-sectional area; cT1: Iron-corrected T1 mapping; CVP: Central venous pressure; ECG: Electrocardiogram; EL: Viscous energy loss rate; KE: Kinetic energy; LPA: Left pulmonary artery; PA: Pulmonary artery; PDFF: Proton density fat-fraction; RPA: Right pulmonary artery; SVC: Superior vena cava; TCPC: Total cavopulmonary connection; VO₂: Peak oxygen uptake.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12968-022-00854-4.

Additional file 1: Table S1. CMR acquisition details. TableS2. Correlation analysis between cross-sectional area of the TCPC segments and 4D flow CMR energetics. TableS3. Correlation analysis between demographic and CMR parameters with exercise capacity and liver cT1 mapping. Fig. S1. A flow chart of the study methods and performed analyses.

Acknowledgements
None.

Authors’ contributions
FR participated in the conception and design of the study and performed all image acquisition, image analysis and statistical analysis of data, contributed to the interpretation of data and drafted the manuscript. JW participated in study conception and design, contributed in image acquisition and interpretation of data and revised the manuscript. AR and HL participated in study conception and design, contributed in interpretation of data and revised the manuscript. PB contributed to interpretation of the data and image acquisition. HA contributed in interpretation of data, development of software used in this study and revised the manuscript. JG contributed in development of software used in this study and revised the manuscript. All authors provided the manuscript, provided critical feedback and approved the submitted version. All authors read and approved the final manuscript.

Funding
F.M.R. and H.C.v.A are funded by a research grant from Stichting Harte-land. F.M.R. is funded by the Dutch Heart Foundation (CVON-2017-08-RADAR). H.C.v.A and F.M.R., E.G.W. and H.C.v.A are funded by a research grant from Stichting Harteland.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study was approved by the medical ethical review board of the Leiden University Medical Center (P18-024). Written informed consent was obtained from all patients and/or their parents.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Cardiothoracic Surgery, Leiden University Medical Center, Albinusdreef 2, 2333ZA Leiden, The Netherlands. 2Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. 3Department of Pediatric Cardiology, Leiden University Medical Center, Leiden, The Netherlands. 4Department of Cardiology and Anatomy and Embryology, Leiden University Medical Center, Leiden, The Netherlands. 5Department of Pediatric Cardiology, Utrecht Medical Center, Utrecht, The Netherlands. 6Department of Radiology, Utrecht Medical Center, Utrecht, The Netherlands.

Received: 9 January 2022 Accepted: 15 March 2022
Published online: 28 March 2022

References
1. Goldberg DJ, Surrey LF, Glaz AC, Dodds K, O’Byrne ML, Lin HC, Fogel M, Rome J, Rand EB, Russo P, Rychlik J. Hepatic fibrosis is universal following fontan operation, and severity is associated with time from surgery: a liver biopsy and hemodynamic study. J Am Heart Assoc. 2017;6:1.
2. Paridon SM, Mitchell PD, Colan SD, Williams RV, Blaufox A, Li JS, Margossian R, Mital S, Russell J. Rhodes J and Pediatric Heart Network: A cross-sectional study of exercise performance during the first 2 decades of life after the Fontan operation. J Am Coll Cardiol. 2008;52:99–107.
3. Haggerty CM, Restrepo M, Tang E, de Zellicourt DA, Sundareswaran KS, Mirabella L, Bethel J, Whitehead KK, Fogel MA, Yoganathan AP. Fontan hemodynamics from 100 patient-specific cardiac magnetic resonance studies: a computational fluid dynamics analysis. J Thorac Cardiovasc Surg. 2014;148:1481–9.
4. Rijnberg FM, Hazekamp MG, Wentzel JJ, de Koning PH, Westenberg JJM, Jongbloed MRM, Blom NA, Roest AAW. Energetics of blood flow in cardiovascular disease: concept and clinical implications of adverse energetic in patients with a fontan circulation. Circulation. 2018;137:2393–407.
5. Tang E, Restrepo M, Haggerty CM, Mirabella L, Bethel J, Whitehead KK, Fogel MA, Yoganathan AP. Geometric characterization of patient-specific total cavopulmonary connections and its relationship to hemodynamics. JACC Cardiovascular Imaging. 2014;7:215–24.
6. Trusty PM, Wei ZA, Rychlik J, Graham A, Russo PA, Surrey LF, Goldberg DJ, Yoganathan AP, Fogel MA. Cardiac magnetic resonance-derived metrics are predictive of liver fibrosis in fontan patients. Ann Thorac Surg. 2020;109:1904–11.
7. Khiabani RH, Whitehead KK, Han D, Restrepo M, Tang E, Bethel J, Paridon SM, Fogel MA, Yoganathan AP. Exercise capacity in single-ventricle patients after Fontan correlates with haemodynamic energy loss in TCPC. Heart. 2015;101:139–43.
8. Rijnberg FM, Elbaz MSM, Westenberg JJM, Kamphuis VP, Helbing WA, Kroft LJ, Blom NA, Hazekamp MG, Roest AAW. Four-dimensional flow magnetic resonance imaging-derived blood flow energetics of the inferior vena cava-to-extracardiac conduit junction in Fontan patients. Eur J Cardiothorac Surg. 2019;55:1202–10.
9. Rijnberg FM, van Assen HC, Hazekamp MG, Roest AAW. Tornado-like flow in the Fontan circulation: insights from quantification and visualization of viscous energy loss rate using 4D flow MRI. Eur Heart J. 2019;40:2170.
10. Rijnberg FM, van Assen HC, Hazekamp MG, Roest AAW, Westenberg JJM. Hemodynamic consequences of an undersized extracardiac conduit in an adult Fontan patient revealed by 4-dimensional flow magnetic resonance imaging. Circ Cardiovasc Imaging. 2021;14:e012612.
11. Godfrey S. Exercise testing in children: applications in health and disease. Saunders Limited; 1974.
12. Ten Harkel AD, Takken T, Van Osch-Gevens M, Helbing WA. Normal values for cardiopulmonary exercise testing in children. Eur J Cardiothorac Rehabil. 2011;18:49–54.
13. Schampaan JJ, Tushuizen ME, Coenaard MJ, Lamb HJ. Multimetric MRI in patients with nonalcoholic fatty liver disease. J Magn Reson Imaging. 2021;53:1623–31.
14. Kendall TJ, Stedman B, Hacking N, Haw M, Vettukattill JJ, Salmon AP, Cope RJ, Sheron N, Millward-Sadler H, Veldman GR, Iredale JP. Hepatic fibrosis and cirrhosis in the Fontan circulation: a detailed morphological study. J Clin Pathol. 2021;53:1623–31.
15. Kendall TJ, Stedman B, Hacking N, Haw M, Vettukattill JJ, Salmon AP, Cope RJ, Sheron N, Millward-Sadler H, Veldman GR, Iredale JP. Hepatic fibrosis and cirrhosis in the Fontan circulation: a detailed morphological study. J Clin Pathol. 2021;53:1623–31.
16. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Ronco JJ, Tousoulis D, Yoganathan AP, Fogel MA, Yoganathan AP. Exercise capacity in single-ventricle patients after Fontan correlates with haemodynamic energy loss in TCPC. Heart. 2015;101:139–43.
17. Godfrey S. Exercise testing in children: applications in health and disease. Saunders Limited; 1974.
18. Ten Harkel AD, Takken T, Van Osch-Gevens M, Helbing WA. Normal values for cardiopulmonary exercise testing in children. Eur J Cardiothorac Rehabil. 2011;18:49–54.
19. Schampaan JJ, Tushuizen ME, Coenaard MJ, Lamb HJ. Multimetric MRI in patients with nonalcoholic fatty liver disease. J Magn Reson Imaging. 2021;53:1623–31.
20. Kendall TJ, Stedman B, Hacking N, Haw M, Vettukattill JJ, Salmon AP, Cope RJ, Sheron N, Millward-Sadler H, Veldman GR, Iredale JP. Hepatic fibrosis and cirrhosis in the Fontan circulation: a detailed morphological study. J Clin Pathol. 2021;53:1623–31.
21. Banerjee R, Pavlides M, Tunncliffe EM, Pechnik SK, Sarania N, Philips R, Collier JD, Booth JC, Schneider JE, Wang LM, Delaney DW, Fleming KA, Robson MD, Barnes E, Neubauer S. Multimetric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 2014;60:69–77.
22. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins BJ. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462–8.
17. Mojtahed A, Kelly CJ, Herlihy AH, Kin S, Wilman HR, McKay A, Kelly M, Milanesi M, Neubauer S, Thomas EL, Bell JD, Banerjee R, Harrisigham I. Reference range of liver corrected T1 values in a population at low risk for fatty liver disease—a UK Biobank sub-study, with an appendix of interesting cases. Abdom Radiol (NY). 2019;44:72–84.
18. Bachta V, Kelly MD, Wilman HR, Jacobs J, Newbould R, Kelly CJ, Gyngell ML, Groves KE, McKay A, Herlihy AH, Fernandes CC, Halberstadt M, Maguire M, Jayaratne N, Linden S, Neubauer S, Banerjee R. Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver. PLoS One. 2019;14:e0214921.
19. Rijnberg FM, Juffermans JF, Hazeckamp MG, Helbing WA, Lamb HJ, Roest AAW, Westenberg JJM, van Assen HC. Segmental assessment of blood flow efficiency in the total cavopulmonary connection using four-dimensional flow magnetic resonance imaging: vortical flow is associated with increased viscous energy loss rate. Eur Heart J Open. 2021;1:1.
20. Elbaz MS, van der Geest RJ, Calkeeen EE, de Roos A, Lelieveldt BP, Roest AA, Westenberg JJ. Assessment of viscous energy loss and the association with three-dimensional vortex ring formation in left ventricular inflow: In vivo evaluation using four-dimensional flow MRI. Magn Reson Med. 2017;77:794–805.
21. Juffermans JF, Westenberg JJM, van den Boogaard PJ, Roest AAW, van Assen HC, van der Palen RLF, Lamb HJ. Reproducibility of Aorta Segmentation on 4D Flow MRI in Healthy Volunteers. J Magn Reson Imaging. 2021;53:1268–79.
22. Kamphuis VP, van der Palen RLF, de Koning PJH, Elbaz MSM, van der Geest RJ, de Roos A, Roest AAW, Westenberg JJM. In-scan and scan-rescan assessment of LV in- and outflow volumes by 4D Flow MRI versus 2D planimetry. J Magn Reson Imaging. 2018;47:511–22.
23. Kamphuis VP, Westenberg JJM, van der Palen RLF, van den Boogaard PJ, van der Geest RJ, de Roos A, Blom NA, Roest AAW, Elbaz MSM. Scan-rescan reproducibility of diastolic left ventricular kinetic energy, viscous energy loss and vorticity assessment using 4D flow MRI: analysis in healthy subjects. Int J Cardiovasc Imaging. 2018;34:905–20.
24. van der Palen RLF, Roest AAW, van den Boogaard PJ, de Roos A, Blom NA, Westenberg JJM. Scan-rescan reproducibility of segmental aortic wall shear stress as assessed by phase-specific segmentation with 4D flow MRI in healthy volunteers. MAGMA. 2018;31:653–63.
25. Rijnberg FM, Juffermans JF, Hazeckamp MG, Helbing WA, Lamb HJ, Roest AAW, Westenberg JJM, van Assen HC, Nagy E. Segmental assessment of blood flow efficiency in the total cavopulmonary connection using four-dimensional flow magnetic resonance imaging: vortical flow is associated with increased viscous energy loss rate. Eur Heart J Open. 2021;1:1.
26. Sundareswaran KS, Pekkan K, Dasi LP, Whitehead K, Sharma S, Kanter KR, Fogel MA, Yoganathan AP. The total cavopulmonary connection resistance: a significant impact on single ventricle hemodynamics at rest and exercise. Am J Physiol Heart Circ Physiol. 2008;295:H2427–35.
27. Dasi LP, Krishnankuttyrema R, Kitajima HD, Pekkan K, Sundareswaran KS, Fogel M, Sharma S, Whitehead K, Kanter K, Yoganathan AP. Fontan hemodynamics: importance of pulmonary artery diameter. J Thorac Cardiovasc Surg. 2009;137:560–4.
28. Whitehead KK, Pekkan K, Kitajima HD, Paridon SM, Yoganathan AP, Fogel MA. Nonlinear power loss during exercise in single-ventricle patients after the Fontan: insights from computational fluid dynamics. Circulation. 2007;116:16165–71.
29. Evans WN, Acherman RJ, Mayman GA, Galindo A, Rothman A, Winn BJ, Yumiaco LS, Restrepo HO. The rate of hepatic fibrosis progression in patients post-fontan. Pediatr Cardiol. 2020;41:905–9.
30. de Lange C, Thranie KD, Thomassen KS, Geier O, Nguyen B, Tomerstedt A, Ording Müller LS, Thaulow E, Almasr R, Dahlen G, Sutherland KR, Möller T. Hepatic magnetic resonance T1-mapping and extracellular volume fraction compared to shear-wave elastography in pediatric Fontan-associated liver disease. Pediatr Radiol. 2021;51:66–76.
31. Cibis M, Jarvis K, Markl M, Rose M, Rigby C, Barker AJ, Wentzel JJ. The effect of resolution on viscous dissipation measured with 4D Flow MRI in patients with Fontan circulation: Evaluation using computational fluid dynamics. J Biomech. 2015;48:2984–9.
32. van der Woude SFS, Rijnberg FM, Hazeckamp MG, Jongbloed MRM, Kenjeres S, Lamb HJ, Westenberg JJM, Roest AAW, Wentzel JJ. The influence of respiration on blood flow in the Fontan circulation: insights for imaging-based clinical evaluation of the total cavopulmonary connection. Front Cardiovasc Med. 2021;8:683849.
33. Tang E, Wei ZA, Trusty PM, Whitehead KK, Mirabella L, Veneziani A, Fogel MA, Yoganathan AP. The effect of respiration-driven flow waveforms on hemodynamic metrics used in Fontan surgical planning. J Biomech. 2019;82:87–95.
34. Bastkowski R, Birdemann R, Brockmeier K, Weiss K, Mainz D, Giese D. Respiration dependency of caval blood flow in patients with Fontan circulation: quantification using 5D Flow MRI. Radiol Cardiothorac Imaging. 2019;1:e190005.
35. Pavlides M, Banerjee R, Sellwood J, Kelly CJ, Robson MD, Booth JC, Collier J, Neubauer S, Barnes E. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 2016;64:308–15.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more: biomedcentral.com/submissions